Published DateClear

Start Date

End Date

Category

• Pipeline2
• Research1

Organizations

• Claris Bio1
• Luxa Biotechnology1

Tags

• Retina543
• Clinical Trials492
• Products483
• Research422
• Technology337
• FDA329
• AMD285
• Glaucoma248
• Eye Drops246
• Dry Eye202

• Tags: stem cell therapy✕

Clear all

Pipeline

Claris Bio raises $118M to advance first-ever LSCD therapy

Financing to support ongoing and planned clinical trials evaluating CSB-001 (oremepermin alfa ophthalmic solution) as a topical ocular biologic eye drop.

Pipeline

Luxa Biotechnology releases FIH data on RPE cell therapy for dry AMD

Stem cell-based replacement therapy shows potential with substantial BCVA gains in worse-seeing and reversal of disease trajectory in better-seeing patients.

Research

Stem cell therapy trial for cornea regeneration reports promising short-term data

All patients undergoing CALEC experienced restored cornea surfaces after 12 months.